Content Validation of an Algorithm for the Assessment, Management and Monitoring of Drug-Induced QTc Prolongation in the Psychiatric Population

References

• Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180. doi:10.1002/wps.2042028498599
   PubMed Web of Science ®Google Scholar
• Ringer PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease: a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry. 2014;5:137.25309466
   PubMed Web of Science ®Google Scholar
• Risgaard B, Waagstein K, Winkel BG, et al. Sudden cardiac death in young adults with previous hospital based psychiatric inpatient and outpatient treatment: a nationwide cohort study from Denmark. J Clin Psychiatry. 2015;76:e1122–e1129. doi:10.4088/JCP.14m0974226455676
   PubMed Web of Science ®Google Scholar
• Vohra J. Sudden cardiac death in schizophrenia: a review. Heart Lung Circ. 2020;29:1427–1432. doi:10.1016/j.hlc.2020.07.00332800442
   PubMed Web of Science ®Google Scholar
• Girardin F, Sztajzel J. Cardiac adverse reactions associated with psychotropic drugs. Dialogues Clin Neurosci. 2007;9(1):92–95.
   Google Scholar
• Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf. 2000;23(3):215–228. doi:10.2165/00002018-200023030-0000411005704
   PubMed Web of Science ®Google Scholar
• Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labeling. Drug Saf. 2001;24:323–351. doi:10.2165/00002018-200124050-0000111419561
   PubMed Web of Science ®Google Scholar
• Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82–99. doi:10.4103/0973-1229.10449723678240
   PubMedGoogle Scholar
• Das B, Rawat VS, Ramasubbu SK, Kumar B. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients. Therapie. 2019;74(6):599–609. doi:10.1016/j.therap.2019.03.00831053339
   PubMed Web of Science ®Google Scholar
• Khan Q, Ismail M, Haider I, Khan F. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study. Int J Clin Pharm. 2017;39(6):1256–1264. doi:10.1007/s11096-017-0532-528895028
   PubMed Web of Science ®Google Scholar
• Ames D, Camm J, Cook P, et al. Minimizing the risks associated with significant QTc prolongation in people with schizophrenia: a consensus statement by the Cardiac Safety in Schizophrenia Group. Australas Psychiatry. 2002;10(2):115–124. doi:10.1046/j.1440-1665.2002.00419.x
   Google Scholar
• Abdelmawla N, Mitchell AJ. Sudden cardiac death and antipsychotics Part 2: monitoring and prevention. Adv Psychiatr Treat. 2006;12:100–109. doi:10.1192/apt.12.2.100
   Google Scholar
• Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J. 2014;35(20):1306–1315. doi:10.1093/eurheartj/ehu10024644307
   PubMed Web of Science ®Google Scholar
• Daniel NM, Walsh K, Leach H, Stummer L. Implementation of a QTc-interval monitoring protocol by pharmacists to decrease cardiac risk in at-risk patients in an acute care inpatient psychiatric facility. Ment Health Clin. 2019;9(2):82–87. doi:10.9740/mhc.2019.03.08230842915
   PubMedGoogle Scholar
• Xionga GL, Pinkhasov A, Mangal JP, et al. QTc monitoring in adults with medical and psychiatric comorbidities: expert consensus from the association of medicine and psychiatry. J Psychosom Res. 2020;135:110138. doi:10.1016/j.jpsychores.2020.11013832442893
   PubMed Web of Science ®Google Scholar
• Lambiase PD, de Bono JP, Schilling RJ, et al. British Heart Rhythm Society clinical practice guidelines on the management of patients developing QT prolongation on antipsychotic medication. Arrhythm Electrophysiol Rev. 2019;8(3):161–165. doi:10.15420/aer.2019.8.3.G131463053
   PubMed Web of Science ®Google Scholar
• Al-Khatib SM, Allen Lapointe NM, Kramer JM, et al. A survey of health care practitioners’ knowledge of the QT interval. J Gen Intern Med. 2005;20(5):392–396. doi:10.1111/j.1525-1497.2005.0101.x15963159
   PubMed Web of Science ®Google Scholar
• Fongemie JM, Al-Qadheeb NS, Estes NA, et al. Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case based evaluation. Pharmacotherapy. 2013;33(6):589–597. doi:10.1002/phar.124223529904
   PubMed Web of Science ®Google Scholar
• Zolezzi M, Cheung L. A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population. Neuropsychiatr Dis Treat. 2019;15:105–114. doi:10.2147/NDT.S18647430636876
   PubMed Web of Science ®Google Scholar
• Brod M, Tesler L, Christensen T. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18(9):1263–1278. doi:10.1007/s11136-009-9540-919784865
   PubMed Web of Science ®Google Scholar
• Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452–458.33122341
   PubMed Web of Science ®Google Scholar
• Funk MC, Stern TA. The ABCs of cardiac screening and electrocardiography. Psychiatric Times. 2001;38(2):9–11.
   Google Scholar
• Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793–2867. doi:10.1093/eurheartj/ehv31626320108
   PubMed Web of Science ®Google Scholar
• Polit DF, Beck CT. The content validity index: are you sure you know what’s being reported? Critique and recommendations. Res Nurs Health. 2006;29(5):489–497. doi:10.1002/nur.2014716977646
   PubMed Web of Science ®Google Scholar
• Lmanasreh E, Moles R, Chen TF. Evaluation of methods used for estimating content validity. Res Social Adm Pharm. 2019;15(2):214–221. doi:10.1016/j.sapharm.2018.03.06629606610
   PubMed Web of Science ®Google Scholar
• Wynd CA, Schmidt B, Schaefer MA. Two quantitative approaches for estimating content validity. West J Nurs Res. 2003;25(5):508–518. doi:10.1177/019394590325299812955968
   PubMed Web of Science ®Google Scholar
• Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Res Nurs Health. 2007;30(4):459–467. doi:10.1002/nur.2019917654487
   PubMed Web of Science ®Google Scholar
• Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol. 2012;76(1):48–57. doi:10.1111/bcp.12040
   Web of Science ®Google Scholar
• Broszko M, Cornel N, Stanciu CN. Survey of EKG monitoring practices: a necessity or prolonged nuisance? Am J Psychiatry Resid J. 2017;12(3):6–9. doi:10.1176/appi.ajp-rj.2017.120303
   Google Scholar
• Sandau KE, Funk M, Auerbach A, et al. Update to practice standards for electrocardiographic monitoring in hospital settings: a scientific statement from the American Heart Association. Circulation. 2017;136(19):e273–e344. doi:10.1161/CIR.000000000000052728974521
   PubMed Web of Science ®Google Scholar
• CredibleMeds®. Crediblemeds.org. CredibleMeds: home [Internet]. Available from: https://crediblemeds.org/. Accessed August 14, 2021.
   Google Scholar
• Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13. doi:10.1016/j.psym.2012.11.00123295003
   PubMed Web of Science ®Google Scholar
• Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes. Can Pharm J. 2016;149(3):139–152. doi:10.1177/1715163516641136
   Web of Science ®Google Scholar
• Noel ZR, See VY, Flannery AH. Walk the line - the importance of well-informed interpretation of QT prolongation. Ann Pharmacother. 2021;55(1):123–126. doi:10.1177/106002802093471832536291
   PubMed Web of Science ®Google Scholar
• El-Sherif N, Turitto G, Boutjdir M. Acquired long QT syndrome and electrophysiology of Torsade de Pointes. Arrhythm Electrophysiol Rev. 2019;8(2):122–130. doi:10.15420/aer.2019.8.331114687
   PubMed Web of Science ®Google Scholar
• Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479–487. doi:10.1161/CIRCOUTCOMES.113.00015223716032
   PubMed Web of Science ®Google Scholar
• Vandael E, Vandenberk B, Vandenberghe J, et al. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424–432. doi:10.1007/s11096-017-0446-228281228
   PubMed Web of Science ®Google Scholar
• Bindraban AN, Rolvink J, Berger FA, et al. Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs. Int J Clin Pharm. 2018;40(5):1372–1379. doi:10.1007/s11096-018-0692-y30051227
   PubMed Web of Science ®Google Scholar
• Sharma S, Martijn Bos J, Tarrell RF, et al. Providers’ response to clinical decision support for QT prolonging drugs. J Med Syst. 2017;41:161. doi:10.1007/s10916-017-0803-728866768
   PubMed Web of Science ®Google Scholar
• Li M, Ramos LG. Drug-induced QT prolongation and torsades de pointes. P&T. 2017;42:473–477.28674475
   PubMedGoogle Scholar
• Yusoff MS. ABC of content validation and content validity index calculation. Resource. 2019;11(2):49–54. doi:10.21315/eimj2019.11.2.6
   Google Scholar